| Somatotropin deficiency
Ngenla vs Sogroya
Side-by-side clinical, coverage, and cost comparison for somatotropin deficiency.Deep comparison between: Ngenla vs Sogroya with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSogroya has a higher rate of injection site reactions vs Ngenla based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Sogroya but not Ngenla, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ngenla
Sogroya
At A Glance
SC injection
Once weekly
Growth hormone analog
SC injection
Once weekly
Growth hormone analog
Indications
- Somatotropin deficiency
- Somatotropin deficiency
- Noonan Syndrome
Dosing
Somatotropin deficiency 0.66 mg/kg based on actual body weight administered SC once weekly; individualize dosage based on growth response. When switching from daily growth hormone, initiate NGENLA on the day following the last daily injection.
Somatotropin deficiency (pediatric) 0.16 mg/kg SC once weekly for treatment-naive patients and those switching from daily somatropin.
Noonan Syndrome, SGA, ISS 0.24 mg/kg SC once weekly for treatment-naive patients and those switching from daily somatropin.
Somatotropin deficiency (adult) Initiate 1.5 mg SC once weekly; titrate every 2-4 weeks by 0.5-1.5 mg to desired response; maximum 8 mg once weekly.
Contraindications
- Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
- Hypersensitivity to somatrogon-ghla or any excipient in NGENLA
- Closed epiphyses
- Active malignancy
- Active proliferative or severe non-proliferative diabetic retinopathy
- Prader-Willi syndrome with severe obesity, history of upper airway obstruction or sleep apnea, or severe respiratory impairment
- Acute critical illness after open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
- Hypersensitivity to somapacitan-beco or any excipient
- Pediatric patients with closed epiphyses
- Active malignancy
- Active proliferative or severe non-proliferative diabetic retinopathy
- Pediatric patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment
Adverse Reactions
Most common (>=5%) Injection site reactions, nasopharyngitis, headache, pyrexia, anemia, cough, vomiting, hypothyroidism, abdominal pain, rash, oropharyngeal pain
Serious Increased mortality in acute critical illness, severe hypersensitivity, increased risk of neoplasm, glucose intolerance and diabetes mellitus, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, progression of preexisting scoliosis, pancreatitis, lipoatrophy, sudden death in pediatric patients with Prader-Willi syndrome
Postmarketing Osteonecrosis in pediatric patients
Most common (>=5%) Nasopharyngitis, respiratory tract infection, pyrexia, headache, pain in extremity, injection site reaction, diarrhea, vomiting, cough, ear infection
Serious Increased mortality in acute critical illness, severe hypersensitivity, neoplasm risk, glucose intolerance and diabetes mellitus, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, scoliosis progression, pancreatitis, lipohypertrophy/lipoatrophy, sudden death in Prader-Willi syndrome patients
Postmarketing Osteonecrosis in pediatric patients
Pharmacology
Somatrogon-ghla is a human growth hormone analog that binds to the GH receptor and activates the STAT5b signaling pathway, increasing serum IGF-1 concentrations and stimulating linear growth and metabolic changes in pediatric patients with growth hormone deficiency.
Somapacitan-beco is a human growth hormone (hGH) analog that binds to a dimeric GH receptor in the cell membrane of target cells, triggering intracellular signal transduction and pharmacodynamic effects mediated both directly and through IGF-1 produced in the liver.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ngenla
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Sogroya
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Ngenla
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (4/8)
Sogroya
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Ngenla
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Sogroya
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/momo
Ngenla Copay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Sogroya.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NgenlaView full Ngenla profile
SogroyaView full Sogroya profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.